India’s pharmaceutical sector is witnessing unprecedented growth, with exports projected to surpass $30 billion by the end of 2025. At the same time, the domestic pharmaceutical market is expected to double to $130 billion by 2030, according to government projections. These developments underscore India’s strengthening role in the global healthcare industry.
As of September 2025, India’s pharmaceutical exports stood at approximately $27.8 billion. The Union Minister of State for Science and Technology, Dr. Jitendra Singh, confirmed that the sector is on track to achieve the $30 billion mark before year-end. This milestone highlights India’s sustained competitiveness in the global pharmaceutical arena despite various challenges, including recent trade barriers in key markets.
The United States continues to be a major destination for Indian pharmaceutical products, accounting for over one-third of the nation’s exports. However, recent measures by the U.S., including a 100% tariff on certain drug imports, have posed challenges to growth. Industry experts note that India’s diverse export portfolio, which includes generic medicines, biosimilars, and specialty drugs, has enabled the sector to sustain robust export performance.
Domestically, India’s pharmaceutical industry is valued at around $60 billion. Government projections indicate that this figure could rise to $130 billion by 2030. This growth is driven by expanding healthcare infrastructure, increasing health insurance coverage, rising disposable incomes, and a growing middle-class population demanding affordable and quality medicines.
The MedTech sector is also recording impressive expansion, with annual growth rates of 15% to 20%. A recent Memorandum of Understanding between the Department of Biotechnology and the Uttar Pradesh Promote Pharma Council aims to further fuel innovation, investment, and production capabilities in pharmaceuticals and biotechnology.
Strategic government initiatives have played a critical role in this upward trajectory. Policy reforms aimed at promoting research and development, manufacturing excellence, and export facilitation have positioned India as a key player in the global pharmaceutical sector. This includes incentives for domestic manufacturing under schemes such as Production Linked Incentives (PLI) and support for innovation hubs.
Looking ahead, the Indian pharmaceutical industry aims to strengthen its global export footprint while meeting the increasing domestic demand. By 2030, India aspires to be among the top five global pharmaceutical exporters, with a diversified portfolio that includes generics, biosimilars, vaccines, and specialty drugs. Analysts suggest that sustained investment in R&D and infrastructure will be essential to achieve this goal.
Conclusion:
India’s pharmaceutical sector stands at the cusp of transformative growth, driven by strong export performance and a rapidly expanding domestic market. With targeted policy support and strategic investments, India is poised to consolidate its position as a global hub for affordable, high-quality medicines.
